Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Power List / 2023 / Leaders and Advocates / Jennifer Van Eyk

Jennifer Van Eyk

Professor, Advanced Clinical Biosystems Research Institute; Director, Precision Biomarker Laboratories; Founder and Director, Smidt Heart Institute, Cedars-Sinai Medical Center, USA

  • Profile

Meet Jennifer Van Eyk

The decade’s most important development?Proteomics! The power of proteomic approaches is that they bring the best of both hypothesis-driven and hypothesis-generation research together. Proteomics technologies allow you to ask key questions, but the data provides a larger set of information about the cell, tissue or body fluid. Although one can focus on specific proteins or pathways, it is impossible to ignore the broader system responses. This ensures that one does not try to fit the data into a preconceived box, but instead pushes one to contemplate the remarkable complexity of biology and how little we still know. 

Biggest challenge facing the field? The infrastructure and cost effectiveness of moving candidate biomarkers into clinical applications is, in my view, the biggest hurdle for the future applications to medicine. 

Missing from the toolbox?Without cell and organ specificity proteome to cell and organ specific function (and yes, you can add in structure), we will not be able to move our global understanding to the complexity of systems.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.